Because of immunosuppressive therapy following liver transplantation, de novo malignancies can occur, and the most common are skin cancers.
A team of investigators sought to assess the impact of risk-reducing salpingo-oophorectomy on breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants.
Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Investigators report findings from the RATIONALE307 trial that assessed treatment with tislelizumab in patients with squamous NSCLC.
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
A team of investigators conducted a retrospective study to determine the relationship of intrinsic breast cancer subtypes on survival in patients undergoing endocrine therapy plus ribociclib.
Investigators report on findings from the MARIETTA study, which evaluated an intensive, CNS-directed chemoimmunotherapy followed by autoHSCT in patients with secondary CNS lymphoma.
The FDA has approved Opdivo (nivolumab) plus chemotherapy for the first-line treatment of patients with gastric cancer.